The US FDA should explore administrative steps within the existing Hatch-Waxman framework to smooth the abbreviated new drug application (ANDA) process for complex generics, but congressional tweaking of the landmark law might be necessary, commissioner-nominee Scott Gottlieb said at his April 5 Senate confirmation hearing.
FDA needs to “develop better scientific principles” for assuring substantial equivalence of ANDA products when traditional measures of bioequivalence may...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?